Neopterin as a novel marker; well correlated with mortality and morbidity in patients with advanced systolic heart failure

Demir, Şerafettin; Ede, Hüseyin; Kaplan, Mehmet; Yavuz, Fethi; Yücel, Celal; Kurt, Ibrahim Halil

doi:10.1080/00015385.2018.1478266

Cited by 5 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Demir et al demonstrated that neopterin is a powerful marker of inflammation in patients with HF. Thus, it can be used in the diagnosis of HF [ 23 ]. Moreover, they found that within 1-year follow-up, patients with high morbidity and mortality had higher levels of neopterin concentrations as compared to patients without risk of morbidity or mortality.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, they found that within 1-year follow-up, patients with high morbidity and mortality had higher levels of neopterin concentrations as compared to patients without risk of morbidity or mortality. One-year follow-up hospitalisation also correlated well with neopterin serum levels making it a valuable marker for disease prognosis [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

“…It has been demonstrated that both levels of NT-Pro BNP and neopterin are elevated in patients with New York Heart Classification (NYHA) class II-IV HF [23][24][25][26]. Moreover, traditional therapies of HF demonstrated their ability to decrease those biomarkers as a part of their role to improve the patient's condition.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients

Dogheim

Khairat

Omran

et al. 2022

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Purpose Heart rate reduction (HR) is a cornerstone in heart failure therapy as it improves patient outcomes. The aim of this study is to evaluate short-term effect of ivabradine on NT-Pro BNP and neopterin in heart failure patients and assess the association between HR and these biomarkers. Methods Sixty patients on standard heart failure therapy were randomly allocated into ivabradine group (n = 30) and non-ivabradine group (n = 30). Ivabradine 5 mg twice daily was given for 3 months. Lipid profile and kidney functions were performed and blood samples for NT-Pro BNP and neopterin were analysed at baseline and after 3 months of intervention in both groups. Results There was a significant improvement in NYHA class in ivabradine group (p < 0.001). Ejection fraction was improved in ivabradine and non-ivabradine groups after intervention (p < 0.001), with a greater improvement in ivabradine group (p = 0.026). Heart rate was reduced in ivabradine group (p < 0.001) and non-ivabradine group (p < 0.001) yet greater reduction was seen in ivabradine group (p < 0.001). Serum creatinine and blood urea nitrogen were reduced in ivabradine group (Scr: p = 0.001, BUN: p = 0.001). NT-Pro BNP and neopterin levels significantly decreased in ivabradine group (NT-Pro BNP: p < 0.001, neopterin p < 0.001). Significant positive correlation was found between HR and biomarker levels after intervention (NT-Pro BNP: r = 0.475, p < 0.001, neopterin: r = 0.384, p = 0.002). Conclusion Ivabradine therapy reduced levels of both biomarkers which correlated well with HR. Biomarker levels might provide a tool for assessing ivabradine effectiveness in HF. Trial registration Date: June 26, 2020. Identifier: NCT04448899. Link: Ivabradine in Patients with Congestive Heart Failure—Full Text View—ClinicalTrials.gov.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients

Dogheim

Khairat

Omran

et al. 2022

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…Authors found a correlation between elevation of urine Neopterin levels and cardiac structural and functional abnormalities evaluated by echocardiography in those patients (Shao et al 2014). Demir et al evaluated in a prospective study the connection between serum neopterin levels and morbidity and mortality due to HF (Demir et al 2019). Average neopterin serum concentration was significantly higher in the HF group compared to the control (Demir et al 2019).…”

Section: Neopterin In Congestive Heart Failurementioning

confidence: 99%

Role of neopterin as an inflammatory biomarker in congestive heart failure with insights on effect of drug therapies on its level

2022

View full text Add to dashboard Cite

Inflammation has a major role in the pathogenesis of heart failure (HF). It triggers a cascade that leads to the release of pro-inflammatory cytokines which in turn cause cardiac hypertrophy, fibrosis, apoptosis, negative inotorpy and leukocyte recruitment which worsen the condition. Neopterin is an inflammatory biomarker which is released as a response to macrophage activation. Levels of neopterin are elevated in conditions which has an immunological component such as autoimmune disease, viral and bacterial infections and malignancy. Neopterin levels were found to be elevated in patients with HF. This is due to the fact that inflammation takes place during the development of the condition. Studies demonstrated that neopterin can be used as a biomarker for diagnosing HF, determining severity of the disease and monitoring its progression. Neopterin levels were higher in patients with New York Heart Association classification (NYHA) III–IV more than class I–II. Moreover, neopterin levels correlated well with morbidity and mortality. It has been suggested that neopterin be monitored levels to determine effectiveness of HF treatment options. Graphical abstract

show abstract

“…К биологическим маркерам воспаления, привлекающим внимание исследователей, относится неоптерин (НП), являющийся неспецифическим и высокочувствительным фактором активации моноцитарного звена клеточного иммунитета и усиленной выработки активных субстанций кислорода при различных патологических состояниях [8].…”

unclassified

Neopterin is a biomarker of chronic heart failure (review of modern literature)

et al. 2021

View full text Add to dashboard Cite

Inflammation plays a role in the pathogenesis of heart failure. Neopterin, pteridine, synthesized mainly by activated macrophages, is a marker of inflammation, activation of the immune system, and an active participant in cardiovascular disease. Measuring neopterin levels can help track the evolution of specific inflammatory conditions. In addition, neopterin was associated with cardiac dysfunction after cardiac surgery and improved the accuracy of predicting the risk of postoperative cardiac dysfunction. In this review, we provide current insights into neopterin and its relationship to heart failure.

show abstract

Neopterin as a novel marker; well correlated with mortality and morbidity in patients with advanced systolic heart failure

Abstract: Neopterin is a biomarker reflecting ongoing inflammatory process in deteriorating heart. High level of serum neopterin concentrations was associated with mortality and morbidity in systolic HF.

Cited by 5 publications

References 22 publications

Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients

Clinical comparative study assessing the effect of ivabradine on neopterin and NT-Pro BNP against standard treatment in chronic heart failure patients

Role of neopterin as an inflammatory biomarker in congestive heart failure with insights on effect of drug therapies on its level

Neopterin is a biomarker of chronic heart failure (review of modern literature)

Contact Info

Product

Resources

About